Panaxia Pharmaceutical Industries has announced a partnership with the Rafa pharmaceutical organization to conduct clinical study of cannabis concentrate inhalation.

The major objective of the study is to improve accessibility for cancer individuals who have been making use of cannabis to treat acute discomfort but favor not to smoke.

“Every clinical study that assists handle therapy making use of healthcare cannabis is vital,” mentioned Sheba Hospital Director, Dr. Itay Gur-Areyeh, M.D. in a news release. “Delivering therapy by way of inhalation is characterized by a faster response time than oral or sublingual tablets.”

The two Israeli firms will be examining the bioavailability of cannabis concentrates making use of an inhaler with an attached vaporizer. Sufferers will be capable to add precisely-measured doses of cannabis extracts to the device for inhalation.

Rafa CEO, Anat Savion says that the future of healthcare cannabis therapy depends on the capacity to match it to every patient in the very best achievable way.

“This clinical trial is performed as element of the registration process of the new items which we are about to launch in Israel this year, in collaboration with Rafa,” mentioned Panaxia CEO, Dr. Dadi Segal. “Through access to cannabis inhalers, and topic to a healthcare specialist’s recommendation, we strive to support much more individuals suffering from acute discomfort.”

Rafa mentioned that the inhaler will supply individuals that are unable or unwilling to smoke, the ideal to be treated regularly and precisely.

With the study currently underway, items are anticipated to arrive at Israeli pharmacies sometime in 2019 below Rafa’s healthcare cannabis brand.

Image: Rafa


68